Home
Storia in 11 fonti
Lilly’s triple agonist still leads among late-stage obesity assets
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the strongest weight loss data yet in Phase 3 trial in a pure obesity population.
- ·
statnews.com
Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.
- ·
nbcnews.com
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.
